Inhibition of Plasmodium Liver Infection by Ivermectin

Antimicrob Agents Chemother. 2017 Jan 24;61(2):e02005-16. doi: 10.1128/AAC.02005-16. Print 2017 Feb.

Abstract

Avermectins are powerful endectocides with an established potential to reduce the incidence of vector-borne diseases. Here, we show that several avermectins inhibit the hepatic stage of Plasmodium infection in vitro Notably, ivermectin potently inhibits liver infection in vivo by impairing parasite development inside hepatocytes. This impairment has a clear impact on the ensuing blood stage parasitemia, reducing disease severity and enhancing host survival. Ivermectin has been proposed as a tool to control malaria transmission because of its effects on the mosquito vector. Our study extends the effect of ivermectin to the early stages of mammalian host infection and supports the inclusion of this multipurpose drug in malaria control strategies.

Keywords: Plasmodium; avermectins; ivermectin; liver stage; malaria.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cell Line, Tumor
  • Culicidae
  • Humans
  • Ivermectin / analogs & derivatives*
  • Ivermectin / therapeutic use*
  • Liver / parasitology*
  • Malaria / drug therapy*
  • Plasmodium / drug effects*
  • Plasmodium / pathogenicity*

Substances

  • Ivermectin
  • avermectin